• Теги
    • избранные теги
    • Компании2366
      • Показать ещё
      • Показать ещё
      Страны / Регионы369
      • Показать ещё
      • Показать ещё
      Международные организации25
      • Показать ещё
      • Показать ещё
      • Показать ещё
Выбор редакции
19 мая, 17:20

Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab

Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.

Выбор редакции
18 мая, 16:23

AbbVie Down on Humira Patent Loss: Is More Damage in Store?

AbbVie Inc.'s (ABBV) shares declined more than 2% on Wednesday after it lost a lawsuit related to a patent protecting its key rheumatoid arthritis drug, Humira to small biotech Coherus BioSciences, Inc. (CHRS),

17 мая, 17:01

Allergan's Irritable Bowel Drug Viberzi Approved in Canada

Allergan plc (AGN) announced that Health Canada approved Viberzi (eluxadoline) for the treatment of adults suffering with irritable bowel syndrome with diarrhea (IBS-D)

17 мая, 16:59

Cardiome (CRME) Q1 Loss Wider Than Expected, Sales Miss

Cardiome Pharma Corp. (CRME) reported loss of 20 cents per share in first quarter of 2017. Reported loss is wider than both the Zacks Consensus Estimate of a loss of 15 cents and year-ago loss of 9 cents.

17 мая, 01:13

Aerie's (AERI) Rhopressa NDA Sufficient for FDA Review

Aerie Pharmaceuticals, Inc. (AERI) announced that it has received notification from the FDA about the completion of the initial 60-day review of the NDA for Rhopressa

Выбор редакции
16 мая, 17:02

Карл Икан увеличил свою долю акций в Conduent

Как стало известно, миллиардер и инвестор Карл Икан увеличил свою долю акций в компании Conduent (ранее известной Xerox Global Services), созданной в январе 2017 года путем отделения от корпорации Xerox. Сообщается, что в течение первого квартала текущего года Карл Икан приобрел дополнительно 19,8 млн бумаг компании Conduent, специализирующейся на аутсорсинге бизнес-процессов. Между тем, сообщается, что Икан продал свою долю акций в компаниях Nuance Communications и Allergan, но увеличил пакет акций в фирме Navistar International, занимающейся производствоv грузовиков, а также в производителе пищевых добавок Herbalife.

16 мая, 16:54

Teva (TEVA) Launches Glumetza Generic, Inks Deal with Otsuka

Teva Pharmaceutical Industries Ltd. (TEVA) announced the launch of a generic version of Valeant Pharmaceuticals International, Inc.'s (VRX) diabetes drug, Glumetza, in the U.S.

Выбор редакции
16 мая, 13:10

Карл Икан увеличил свою долю акций в Conduent

Как стало известно, миллиардер и инвестор Карл Икан увеличил свою долю акций в компании Conduent (ранее известной Xerox Global Services), созданной в январе 2017 года путем отделения от корпорации Xerox. Сообщается, что в течение первого квартала текущего года Карл Икан приобрел дополнительно 19,8 млн бумаг компании Conduent, специализирующейся на аутсорсинге бизнес-процессов. Между тем, сообщается, что Икан продал свою долю акций в компаниях Nuance Communications и Allergan, но увеличил пакет акций в фирме Navistar International, занимающейся производствоv грузовиков, а также в производителе пищевых добавок Herbalife.

Выбор редакции
16 мая, 03:14

Icahn takes new 19.8 million share stake in Conduent in first quarter

NEW YORK (Reuters) - Billionaire investor Carl Icahn acquired a new 19.8 million share stake in business services provider Conduent Inc in the first quarter and sold out of pharmaceutical firm Allergan Plc and speech technology group Nuance Communications Inc , according to regulatory filings on Monday.

Выбор редакции
16 мая, 03:09

Several top fund managers trim Allergan stakes in first quarter

NEW YORK (Reuters) - Six closely watched investors sliced their stakes in Allergan Plc during the first quarter, recent regulatory disclosures show, cutting what had been one of the years' best...

15 мая, 03:45

Taking the bull case for Valeant seriously

Last night I had dinner with a friend who had a friend who was buying Valeant. Whatever - it led to a discussion of Valeant fundamentals - and that in turn led to this blog post.The stock has been on a tear lately - rising from $10 to $13.59 in the last week - poking above $14. To some degree this is just standard volatility for a bombed out stock. But it was prompted by Valeant producing results with a sharp rise in "adjusted EBITDA" and guiding for higher adjusted EBITDA. As the FT put it Valeant "bumped guidance".The Valeant adjusted cash flow caperI want to explore this "adjusted EBITDA" number. Then I want to lay out the valuation directly.Valeant has a history of producing little or no GAAP earnings but very large adjusted cash flow. The adjustments are after a collection of exceptions chosen by management and not subject to audit. This blog has demonstrated in the past that some of these exclusions from cash flow are recurring expenses. That said here is the history going back to the final quarter of 2012.QuarterMeasures presented$million2012-04Adjusted Operating Cash Flow4232013-01Adjusted Operating Cash Flow3452013-02Adjusted Operating Cash Flow4232013-03Adjusted Operating Cash Flow4082013-04Adjusted Operating Cash Flow6072014-01Adjusted Operating Cash Flow6362014-02Adjusted Operating Cash Flow5002014-03Adjusted Operating Cash Flow7712014-04Adjusted Operating Cash Flow6242015-01Adjusted Operating Cash Flow7082015-02Adjusted Operating Cash Flow7732015-03Adjusted Operating Cash Flow8652015-04Adjusted Earnings*5412016-01Adjusted Earnings, Adjusted EBITDA**442, 10762016-02Adjusted net income, Adjusted EBITDA***487, 10872016-03Adjusted net income, Adjusted EBITDA#543, 11632016-04Adjusted net income, Adjusted EBITDA##441, 10452017-01Adjusted net income, Adjusted EBITDA###273, 861NOTESAlas this table of changing measures requires some notes.*In the fourth quarter of 2015 the company presented a late annual report. It announced preliminary earnings that contained a new measure: "adjusted EPS". The "adjusted EPS": was not reconciled in any way to previously announced "adjusted cash flow". The "adjusted earnings" in the above table are is the total adjusted earnings that was used to calculate the "adjusted EPS".**In the first quarter of 2016 the company reported an adjusted EPS number and and adjusted EBITDA number  started guiding for an adjusted EBITDA number. You would think this number to be broadly consistent with previously used "adjusted operating cash flow" numbers. It wasn't. Remarkably there was an unexplained mismatch between the 2015 first quarter adjusted EBITDA number and the originally reported "adjusted operating cash flow". The old number was 708 million as in the above table. The new number was 1127 million. Somehow as Valeant was collapsing they surreptitiously changed their adjustment to even further increase their stated adjusted cash flows.***In the second quarter of 2016 the company reported an "adjusted net income" which was inconsistent with previously reported numbers. The previously reported number was "adjusted operating cash flow" of $773 million in the second quarter of 2015. Now they reported "adjusted net income" of $751 million for the same quarter. I cannot reconcile the old $773 million number to the new $751 million number.#In the third quarter of 2016 the company produced an "adjusted earnings" and adjusted EPS number. There is a number for adjusted earnings in the previous corresponding period (that is the third quarter of 2015). That number is $845 million. Again I cannot reconcile this number to the previously stated number.##In the fourth quarter of 2016 the same issue arises but this time with respect to adjusted EBITDA which is now reported as $1374 million in the fourth quarter of 2015.###In the first quarter of 2017 the adjusted EBITDA presented for the first quarter of 2016 was $1008 million. Again it cannot be reconciled to the previously reported $1076 million.Huge cash flows - company is on its kneesIts pretty obvious here that the "adjusted" numbers need to be taken with some salt. Firstly the adjustments simply do not reconcile quarter on quarter. Secondly despite all these adjustments GAAP earnings look limp and the company is on its knees.In the last quarter the GAAP earnings look fine until you realise that more than 100 percent of them come from writing down previously accrued deferred tax liabilities. The earnings are good because the company won't be paying as much tax in the future (possibly because losses are large and unrecoverable).The headline: guiding up non GAAP adjusted EBITDAThat said the headline for the Valeant numbers were that they bumped up guidance for their own non-GAAP measures. (They do not and never have guided GAAP numbers.) Here is the key text:Valeant has raised guidance for 2017, as follows:2017 Full Year Adjusted EBITDA (non-GAAP) in the range of $3.60 - $3.75 billion from $3.55 - $3.70 billionThis guidance reflects the impact of the sale of the CeraVe, AcneFree and AMBI skincare brands. This guidance does not reflect the impact of the sale of the Dendreon business, which is expected to close mid-year.What this does not state is that they missed previously announced revenue guidance - and missed it quite badly.This was the previously announced guidance (announced with the fourth quarter 2016 results):Valeant has provided guidance for 2017 as follows:GAAP Total Revenues in the range $8.90 billion - $9.10 billion,Adjusted EBITDA (non-GAAP) in the range of $3.55 billion - $3.70 billionBut in the first quarter revenue came in at $2.109 billion. That is a really big drop. You would have to think that Valeant is going to miss its annual earnings guidance by $500 million or so. The FT article notes an 11 percent decline in revenue.The common sense testI am an old fashioned sort of guy. There are really only two ways you can raise real EBITDA (and hence I would think that there are only two ways you can raise adjusted EBITDA).The first way is you increase revenues.The second way is you decrease costs.I think that is the end of the story.So Valeant revenues are on track to miss guidance by about half a billion dollars. But they are going to beat their adjusted EBITDA number.This can only be done if they have decreased their costs by an unanticipated half a billion dollars.Possible: but I would like to know what costs they are cutting that they had not previously anticipated.Remember this is a company that was notorious for cutting costs (possibly to excess) whenever they purchased an asset.This was the company who fired almost all non-revenue producing people.Scientists doing research: fire them.Compliance officers: fire them.So I am left with a choice. EitherThe entire myth of Valeant - that it was a ruthlessly low cost operation is bullshit and there are still plenty of unanticipated costs to cut allowing the company to miss on revenue and beat on adjusted EBITDA, or They are cutting hard into revenue producing staff, but this is going to raise adjusted EBITDA or The adjusted EBITDA number and guidance is BS.As you can guess common sense leads me to the third choice. The adjusted EBITDA number and guidance remain BS.Alternative valuation measuresYou can't value this company against the "adjusted EBITDA" because - as this post demonstrates that number is almost certainly BS.You can't value this company against earnings because (other than writing off future tax liabilities) this company has no earnings. So you are left trying to value it against revenue. So lets play this game. Let's presume that Valeant revenue is as good as Gilead revenue. Gilead is of course the super-champion drug company with $90,000 drugs that cure nasty diseases like Hepatitis C. It is one of the finest drug companies in the world - and is strongly profitable.Assuming that Valeant's rag-tag of declining generic drugs with increasing competition is - per dollar of revenue - as good as Gilead - is of course generous.But lets assume that...Gilead Revenue is running at $29 billion per annum. The revenue is declining though because the drug works - and people are being cured of Hepatitis C. The market cap is 86.3 billion and cash and equivalents are 11.9 billion. The enterprise value is just under 75 billion - so this is worth just over 2.5 times sales.If you project pretty gnarly falls on Gilead Revenue (simply because their drug works) it is hard to get below 3 times sales for Gilead.Valeant sales are about $8.4 billion. Put that on three times sales and you can't even cover the debt. The equity will wind up being worth a brass razoo. --Now I am being harsh. Growing pharmaceutical companies with franchises and new drugs in the pipeline regularly trade at 4.5 times sales. If you put Valeant on 4.5 times sales you something in the mid 30 billion range - but only if Valeant sales rapidly stop their catastrophic decline. Valeant debt is about 28.5 billion. That gives you potentially - and this is if everything goes right and you put it all on a pretty decent multiple of revenue - about $7 billion in residual equity value. The market cap is about 4.7 billion now.So if all goes really well you can make some money. But you need to make some pretty heroic assumptions. Firstly you need to assume that the various litigation that is inevitable doesn't impair that too much. (I think it will...)Then you need to assume that the revenue doesn't continue to fall. (I think it will. The company will not be allowed to charge over $200 thousand per year for drugs like Syprine indefinitely. There is probably half a billion to a billion in revenue that will go away simply as competition hits the massively overpriced generics. Actually half a billion is generous.On top of this you have to ignore the inevitable competition that will come to their biggest drug (Xifaxan). That drug will have a generic supplied by Allergan.All up I forsee well over a billion dollars of likely revenue declines.Finally you have to ignore the lack of integrity that allows you to guide up "adjusted EBITDA" when the revenue misses by a lot and where you have not obviously cut costs.Still - if this is the gamble you want - good luck to you. There are easier ways to make money.John

13 мая, 01:02

What David Tepper Bought (Besides SNAP) And Sold In Q1: The Full Breakdown

Yes, David Tepper's Appaloosa bought Snapchat in Q1. No, it wasn't a material amount: he only bought a 100,000 share flier in the name, or under $2.3 million. What is most notable about Tapper's Q1 holdings (aside from the SNAP non-story, of course) is that he took his total long stake to just under $6.1 billion as of March 31, up from $5.6 billion at the end of 2016, and the highest net long exposure since September 2014. Here is a breakdown of the key position changes for Tepper as of March 31: Top new positions: Bank of America, General Motors, CBS, UnitedHealth, Symantec, and Nucor. Top exits: Citizens Financial, Qualcomm, Tempur-Sealy, Comerica and American Airlines Boosted stakes: Micron, Southwest, Boston Scientific, Yahoo, Centene, Western Digital, Kinder Morgan, Summit Materials, ArcelorMittal Cut stakes: Allergan, Teva, Pfizer, Mylan, HCA Healthcare, Allstate, McKesson, Whirlpool, Hain Celestial And the full visual summary: bold are additions; green are new positions; Red are exits. Source: 13F

12 мая, 15:49

Pharma Stock Roundup: Mylan, Teva Q1 Earnings, Roche Drug Misses in Pivotal Study

While companies like Mylan (MYL), Allergan and Teva reported Q1 results this week, several companies provided updates on their cancer drugs.

12 мая, 14:34

Teva (TEVA) Q1 Earnings In Line, Sales Lag as Copaxone Falls

Teva Pharmaceutical Industries Ltd. (TEVA) reported first-quarter 2017 earnings of $1.03 per share (including equity compensation expenses), which was in line with the Zacks Consensus Estimate.

11 мая, 17:32

Impax (IPXL) Q1 Earnings Miss, Stock Up on Cost Savings Plan

Impax Laboratories Inc. (IPXL) posted first-quarter 2017 adjusted earnings of 11 cents per share, missing the Zacks Consensus Estimate of 12 cents. Earnings were down 74.4% from 43 cents in the year-ago period

11 мая, 15:39

Teva (TEVA) Q1 Earnings In-Line, Sales Miss, Shares Up

Teva???s first quarter earnings (including equity compensation expenses), came in at $1.03 per share, in-line with the consensus estimate.

Выбор редакции
Выбор редакции